<u>The usefulness of SARS-CoV-2 test positive proportion as a surveillance tool:</u> <u>Supplementary Appendix</u>

Methods

SEIR model equations

We simulate a stochastic SEIR model with the assumptions stated in the Methods section to model changes in testing capacity over time, using a tau-leaping algorithm. We perform all simulations in a population of 1 million, starting with 100 infectious individuals for a prevalence of 0.01%. We assume no births or deaths over the short time scale of the epidemic, nor immigration of new cases or individuals of any state.

Each of the S, E, I, and R compartments is divided into low-susceptibility (L) and highsusceptibility (H) compartments. High-susceptibility individuals have increased susceptibility to infection ($\beta_H > \beta_L$). Transmission parameters β_L and β_H can vary deterministically over time, according to whether lockdown measures are in place. σ and γ represent the rates of going from the exposed to infectious and infectious to recovered compartments respectively, in the absence of testing (i.e. natural history of the disease).

The demand for testing in each compartment is determined by the proportion of individuals reporting COVID-19 like symptoms (p_I in the E and S compartments, 1 in the I compartment) and the rate of testing among symptomatic/asymptomatic high-/low-susceptibility individuals. The per-capita demand for each compartment is given below:

$$\begin{split} D_{SL} = &(p_I d_{SL} + (1 - p_I) d_{AL}) \\ D_{EL} = &(p_I d_{SL} + (1 - p_I) d_{AL}) \\ D_{IL} = &d_{SL} \\ D_{SH} = &(p_I d_{SH} + (1 - p_I) d_{AH}) \\ D_{EH} = &(p_I d_{SH} + (1 - p_I) d_{AH}) \\ D_{IH} = &d_{SH} \\ D = &D_{SL} + D_{EL} + D_{IL} + D_{SH} + D_{EH} + D_{IH} \end{split}$$

Available tests are represented by the T compartment. New tests are produced at a rate r(t) per day, which can change over time to represent testing capacity strengthening during the epidemic. Tests are used each day according to the supply and demand, encompassed by the function T^{*}. If supply of tests is less than demand, tests are assigned proportional to demand from each compartment, so the rate of testing in each compartment is multiplied by T^{*}/D. Once tests are performed, they are moved into the positive (P) or negative (N), high- (H) or low-susceptibility (L) compartment, depending on which type of individual they were applied to. For example, the T_{PH} compartment represents tests applied to high-risk individuals that returned a positive result. The test has imperfect sensitivity, meaning that a proportion (1-p_s) of tests applied to infected individuals are counted as negative tests, and those individuals are not quarantined.

The differential equations are given below:

$$\begin{split} \frac{dS_L}{dt} &= -\beta_L(t)\frac{(I_L + I_H)}{N}S_L \\ \frac{dE_L}{dt} &= \beta_L(t)\frac{(I_L + I_H)}{N}S_L - \left(\sigma + p_S D_{EL}\frac{T^*}{D}\right)E_L \\ \frac{dI_L}{dt} &= \sigma E_L - \left(\gamma + p_S D_{IL}\frac{T^*}{D}\right)I_L \\ \frac{dS_H}{dt} &= -\beta_H(t)\frac{(I_L + I_H)}{N}S_H \\ \frac{dE_H}{dt} &= \beta_H(t)\frac{(I_L + I_H)}{N}S_H - \left(\sigma + p_S D_{EH}\frac{T^*}{D}\right)E_H \\ \frac{dI_H}{dt} &= \sigma E_H - \left(\gamma + p_S D_{IH}\frac{T^*}{D}\right)I_H \\ \frac{dR}{dt} &= p_S D_{EL}\frac{T^*}{D}E_L + \left(\gamma + p_S D_{IL}\frac{T^*}{D}\right)I_L + p_S D_{EH}\frac{T^*}{D}E_H + \left(\gamma + p_S D_{IH}\frac{T^*}{D}\right)I_H \\ \frac{dT}{dt} &= r(t) - T^* \\ \frac{dT_{PH}}{dt} &= p_S(D_{EL}E_L + D_{IH}I_H)\frac{T^*}{D} \\ \frac{dT_{PL}}{dt} &= p_S(D_{EL}E_L + D_{IL}I_L)\frac{T^*}{D} \\ \frac{dT_{NH}}{dt} &= ((1 - p_S)(D_{EH}E_H + D_{IH}I_H) + D_{SH}S_H)\frac{T^*}{D} \\ \frac{dT_{NL}}{dt} &= ((1 - p_S)(D_{EL}E_L + D_{IL}I_L) + D_{SL}S_L)\frac{T^*}{D} \end{split}$$

Table 1 displays the primary model parameters, their meanings, and values/ranges considered in simulations.

Parameter	Meaning	Default value/range considered
β	Transmission rate (daily per-capita hazard of transmission for a susceptible individual) (days ⁻¹)	Values such that R ₀ is between 3 and 5 pre-lockdown, and between 0.8 and 1 post-lockdown
Lockdown time	Time at which social distancing and other measures are implemented, relative to start of simulation	21-35 days
σ	Rate of becoming infectious for an exposed individual (days ⁻¹)	1/5.2(Lauer et al., 2020; Li et al., 2020)

Table 1: Model parameters and meaning

Y	Rate of becoming recovered for an infectious individual in the absence of testing (days ⁻¹)	1/6 (assumed)
d_S and d_A	Rate of receiving a test for a symptomatic and asymptomatic individual respectively (days ⁻¹)	d _s : 0.05 (0.01-0.2) (assumed) d _A : 3x10 ⁻⁵ (1x10 ⁻⁵ ,1x10 ⁻⁴) (assumed)
рі	Prevalence of non-SARS-CoV-2 CLI among non-infectious population	0.01 (0.005,0.05) (assumed)
ps	Diagnostic test sensitivity	0.95
T _{max}	Daily maximum number of test kits that can be analysed	100 test kits / 100,000 people, increasing linearly over time by 2-5 tests kits / 100,000 per day
рн	Proportion of the population that is in the high-susceptibility group	0.5 (0.2-0.5)
βн	Transmission rate in the high- susceptibility group (days ⁻¹)	2-3 times higher than β_L
d_{SH} and d_{AH}	Rate of receiving a test for a symptomatic and asymptomatic individual respectively in the high-susceptibility group (days ⁻¹)	1-2 times higher than d _{SL} and d _{AL} respectively

Results

Comparing simulation results to theoretical relationships

To check that simulated results were in line with theoretical results, we varied three key testing parameters separately to demonstrate the effect of variation in testing on the relationship: the rate of testing asymptomatic individuals, rate of testing symptomatic individuals, and the proportion of non-infectious individuals presenting COVID-19 like symptoms. We found that simulation results were in line with theoretical results. Observations with above-average testing of symptomatics had lower TPP than the average and higher TSP. Observations with above-average testing of asymptomatics had lower TPP than the average and lower TSP. Finally, observations with above-average proportion of COVID-19 like symptoms among non-infectious individuals had lower TPP than average but higher TSP. In general, TPP seemed to be most sensitive to changes in the d_s and least sensitive to changes in the d_A. In contrast, TSP was most sensitive to changes in the rate of d_A.

Time-varying testing parameters

In the simulations above, TPP was strongly correlated with the rate of positive tests (average Pearson correlation = 0.94 across all simulations in Figure 3). The average correlation was lower for simulations in which there was a shortage of tests relative to demand during the epidemic compared to simulations in which all tests sought were performed (average Pearson correlation 0.92 vs. 0.97). When there is a shortage of tests, TPP rises independently of infectious prevalence.

In addition, we simulated epidemics in which one of three parameters doubled or halved over the first five weeks of the outbreak, linearly over time: the rate of testing asymptomatic individuals, the rate of testing symptomatic individuals, and the prevalence of non-SARS-CoV-2 CLI. For example, if an influenza outbreak were to occur concurrently with a rise in SARS-CoV-2 cases, we would expect the rise in TPP with detected SARS-CoV-2 cases to be lower than if there were no influenza outbreak. In all situations, the TPP remained highly correlated with the weekly number of positive tests: both time series rise and fall in phase, and the magnitude of the rise in TPP does not affect this correlation. Changes in testing parameters on the order that we explored in simulations were unable to produce a situation in which TPP was uncorrelated or anti-correlated with confirmed incidence, although larger, more rapid changes could achieve this.

Effect of differential testing within susceptibility groups

If the population is divided into high- and low-susceptibility groups, the TPP will be higher in the high-susceptibility group due to the group being over-represented among symptomatic individuals. However, the relationship between confirmed incidence rate and TPP remains the same unless the groups are tested at different rates. If we had data on testing rates and cases stratified by susceptibility group (e.g. job category), plotting confirmed incidence against TPP for each susceptibility group can indicate whether there are testing differences between the groups. As seen in Figure S1, there is separation between the average TPP-confirmed incidence relationship if symptomatic high-susceptibility individuals are tested at a higher rate than symptomatic low-susceptibility individuals. On the other hand, the TPP is less sensitive to differences in asymptomatic testing rate (top row, left panel, less separation between pink and black lines and points). TSP is more sensitive to differences in asymptomatic testing rate (between groups (bottom row).

Bibliography

- Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., ... Lessler, J. (2020). The incubation period of coronavirus disease 2019 (CoVID-19) from publicly reported confirmed cases: Estimation and application. *Annals of Internal Medicine*, *172*(9), 577–582. https://doi.org/10.7326/M20-0504
- Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., ... Feng, Z. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *New England Journal of Medicine*, *382*(13), 1199–1207. https://doi.org/10.1056/NEJMoa2001316



Figure S1: Relationship between TPP (top row) and TSP (bottom row) and observed positive tests per 10,000 at 4 weeks from simulations (points) and from the deterministic model (lines). Color denotes the group in which the variables are calculated: low-susceptibility (pink), high-susceptibility (black), and the whole population (green). In the left column, asymptomatic high-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility individuals are tested at a rate 1-2x that of low-susceptibility symptomatic individuals.